title: Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity.
abstract: Reduced plasma HDL cholesterol concentration has been associated with an increased risk of coronary heart disease. However, a low HDL cholesterol concentration is usually not observed as an isolated disorder because this condition is often accompanied by additional metabolic alterations. The objective of this study was to document the relevance of assessing HDL particle size as another feature of the atherogenic dyslipidemia found among subjects with visceral obesity and insulin resistance. For that purpose, an average HDL particle size was computed by calculating an integrated HDL particle size using nondenaturing 4-30% gradient gel electrophoresis. Potential associations between this average HDL particle size versus morphometric and metabolic features of visceral obesity were examined in a sample of 238 men. Results of this study indicated that HDL particle size was a significant correlate of several features of an atherogenic dyslipidemic profile such as increased plasma TG, decreased HDL cholesterol, high apolipoprotein B, elevated cholesterol/HDL cholesterol ratio, and small LDL particles as well as increased levels of visceral adipose tissue (AT) (0.33 < or = absolute value of r < or = 0.61, P < 0.0001). Thus, men with large HDL particles had a more favorable plasma lipoprotein-lipid profile compared with those with smaller HDL particles. Furthermore, men with large HDL particles were also characterized by reduced overall adiposity and lower levels of visceral AT as well as reduced insulinemic-glycemic responses to an oral glucose load. In conclusion, small HDL particle size appears to represent another feature of the high TG- low HDL cholesterol dyslipidemia found in viscerally obese subjects characterized by hyperinsulinemia.
authors.affiliation: Lipid Research Center, CHUL Research Center, Ste-Foy, Québec, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Pascot
authors.forename: I
authors.initials: I
authors.lastname: Lemieux
authors.forename: D
authors.initials: D
authors.lastname: Prud'homme
authors.forename: A
authors.initials: A
authors.lastname: Tremblay
authors.forename: A
authors.initials: A
authors.lastname: Nadeau
authors.forename: C
authors.initials: C
authors.lastname: Couillard
authors.forename: J
authors.initials: J
authors.lastname: Bergeron
authors.forename: B
authors.initials: B
authors.lastname: Lamarche
authors.forename: J P
authors.initials: JP
authors.lastname: Després
mesh_terms: D000005:Abdomen / Q000473:pathology*; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000378:metabolism*; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D005215:Fasting / Q000097:blood; D005951:Glucose Tolerance Test; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood / Q000150:complications / Q000378:metabolism; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000378:metabolism*; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000737:chemistry* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications / Q000378:metabolism*; D010316:Particle Size; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D008075:Lipoproteins, HDL